What changed in Revolution Medicines, Inc.'s latest annual report
In the year ended 31 Dec 2025, Revolution Medicines, Inc.'s total liabilities rose 146.7% to USD 723.21m, from USD 293.10m; cash and cash equivalents fell 29.3% to USD 383.75m, from USD 543.06m; shareholders' equity fell 28% to USD 1.63bn, from USD 2.27bn.
Year ended 31 Dec 2025. Source: 10-K filed 25 Feb 2026, read it on SEC EDGAR.
USD 293.10m to USD 723.21m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 0 | 0 | Not comparable |
| Net income | -600.09m | -1.13bn | Not comparable |
| Total assets | 2.56bn | 2.35bn | Down 8% |
| Total liabilities | 293.10m | 723.21m | Up 146.7% |
| Cash and cash equivalents | 543.06m | 383.75m | Down 29.3% |
| Shareholders' equity | 2.27bn | 1.63bn | Down 28% |
Questions people ask
Did Revolution Medicines, Inc.'s revenue grow last year?
Revenue changed, from USD 0 to USD 0 in the year ended 31 Dec 2025.
Is Revolution Medicines, Inc. profitable?
Not in its latest year: it reported a net loss of USD 1.13bn in the year ended 31 Dec 2025. The year before: a net loss of USD 600.09m.
How much cash and debt does Revolution Medicines, Inc. have?
At its latest year end (31 Dec 2025), Revolution Medicines, Inc. reported cash and cash equivalents of USD 383.75m.
Where do these numbers come from?
From Revolution Medicines, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Revolution Medicines, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%